{
  "id": 20468383,
  "title": "Jefferies reiterates Ardelyx stock rating on contracting strategy",
  "url": "https://urgent.news/2026/11/17/jefferies-reiterates-ardelyx-stock-rating-on-contracting-strategy",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-17T17:50:51.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/jefferies-reiterates-ardelyx-stock-rating-on-contracting-strategy-93CH-5033729"
  },
  "original_language": "en",
  "account": "Jefferies has reaffirmed a Buy rating and $8.00 price target on Ardelyx, Inc (NASDAQ:ARDX), indicating potential upside from the current stock price of $3.12. The investment firm highlighted that Ardelyx plans to adopt a cautious approach to Ibsrela contracting in 2027, aiming to allay investor concerns regarding the gross-to-net ratio. Jefferies anticipates conservative 2027 guidance from the company, coupled with Phase III CIC topline expected in the second half of 2027. Ardelyx's stock has declined by 50% year-to-date, and 51% over the past six months. According to InvestingPro analysis, the stock appears fairly valued at its current level. Investors can access a detailed Pro Research Report on ARDX for additional insights. In a separate development, Ardelyx reported a 19% increase in third-quarter revenue compared to the same period last year, though it fell short of analysts' forecasted $129.22 million, with product revenue reaching $125.5 million. Despite this, net loss narrowed to $700,000, signaling progress towards profitability. Investors seem to be optimistic about the strong demand for Ardelyx's product IBSRELA and the company's reaffirmed full-year guidance, leading to positive market response and growing financial leverage for the biotech firm.",
  "summary": null,
  "key_points": [
    "Jefferies reaffirms Buy rating and $8.00 price target on Ardelyx",
    "Ardelyx plans cautious Ibsrela contracting in 2027 to address investor concerns",
    "Q3 revenue increased 19% year-over-year, net loss narrowed to $700,000"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}